G1 Therapeutics thinks it has a winner on its hands with CDK4/6 inhibitor trilaciclib and is embarking on an initial public offering to give it the resources…

AstraZeneca's European pharma VP is reported to be on "gardening leave" after his employer sues for breaching his employment contract.

Singapore’s state-owned investment firm Temasek and Chinese internet tycoon Jack Ma-backed Yunfeng Capital have led a $75 million Series B into WuXi NextCODE.

Frequency Therapeutics has just raised $32 million in a financing round it hopes will help it bring its therapy for noise-induced hearing loss into the clinic.

Axovant Sciences is capitalizing on the attention it has received from welcoming biotech icon David Hung as its new CEO with a $125 million share offering.

Israel's Bioblast Pharma has abandoned plans for a securities offering, blaming what it called "adverse market conditions" for the decision.

With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.

Visterra has begun efforts to bounce back from its failed IPO attempt by securing a contract from CARB-X.

Blueprint Medicines has filed to raise $150 million to equip itself to take its phase 1 candidates deeper into development.

Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.